Credit Suisse initiates coverage of 23andMe at outperform, says stock can rise 78%

Published Tue, Aug 17 20217:23 AM EDTUpdated Tue, Aug 17 202110:50 AM EDT

Jesse Pound @/in/jesse-pound @jesserpound

Anne Wojcicki, 23andMe co-founder & CEO (right) celebrates with 23andMe employees after remotely ringing the NASDAQ opening bell at the headquarters of DNA tech company 23andMe in Sunnyvale, California, U.S., June 17, 2021.

Peter DaSilva | Reuters

The health care potential of genetics company 23andMe should give investors a massive return, according to Credit Suisse.

More In Analyst Calls

Bank of America double upgrades Robinhood, citing rise in retail trading

Tanaya Macheel

Here are Friday's biggest analyst calls: Nvidia, Tesla, Robinhood, Salesforce, Netflix, Roblox, Chevron, Walmart & more

Michael Bloom

Friday's analyst calls: Chinese e-commerce giant upgraded, chemicals stock to rally 30%

Samantha Subin